HGS stock skyrockets on Glaxo deal talk

Talk is once again raging that GlaxoSmithKline is negotiating to buy Human Genome Sciences for some $4 billion. HGS, which makes an experimental lupus drug, saw its stock soar for the sixth straight day on rumors that Glaxo might make a $30-per-share-offer. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.